Annexon, Inc. (ANNX)
NASDAQ: ANNX · Real-Time Price · USD
2.510
-0.040 (-1.57%)
At close: Jul 25, 2025, 4:00 PM
2.490
-0.020 (-0.80%)
After-hours: Jul 25, 2025, 7:44 PM EDT
Annexon Employees
Annexon had 100 employees as of December 31, 2024. The number of employees increased by 29 or 40.85% compared to the previous year.
Employees
100
Change (1Y)
29
Growth (1Y)
40.85%
Revenue / Employee
n/a
Profits / Employee
-$1,673,800
Market Cap
275.38M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 100 | 29 | 40.85% |
Dec 31, 2023 | 71 | -9 | -11.25% |
Dec 31, 2022 | 80 | 19 | 31.15% |
Dec 31, 2021 | 61 | 13 | 27.08% |
Dec 31, 2020 | 48 | 24 | 100.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ANNX News
- 2 days ago - Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy - GlobeNewsWire
- 11 days ago - Annexon: Lead GBS Therapy Stokes Near-Term Potential - Seeking Alpha
- 5 weeks ago - Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) - GlobeNewsWire
- 2 months ago - Annexon Biosciences to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting - GlobeNewsWire
- 2 months ago - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewsWire
- 2 months ago - Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting - GlobeNewsWire